The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Safi Shahda
Consulting or Advisory Role - Bayer; Celgene
 
Bassel F. El-Rayes
Consulting or Advisory Role - Genentech/Roche; Merrimack; Merrimack
Research Funding - AVEO (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Genentech (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Bert H. O'Neil
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Genentech/Roche; Lilly/ImClone; Sanofi
Speakers' Bureau - Amgen
 
Alexander Starodub
No Relationships to Disclose
 
Wahid Tewfik Hanna
No Relationships to Disclose
 
Laura Borodyansky
No Relationships to Disclose
 
Cindy Oh
No Relationships to Disclose
 
Chiang Li
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Research to Practice; Sanofi; Sirtex Medical; Taiho Pharmaceutical
Other Relationship - Exelixis; Polaris